CG Oncology Celebrates Defining Milestone As Bladder Cancer Trial Succeeds
CG Oncology announced positive topline results from its Phase 3 PIVOT-006 trial on Monday. CEO Arthur Kuan described the results as a defining milestone for the company.
Why it matters — The trial results are a notable company update for investors and others following CG Oncology.